Hochreiter Beatrix, Lindner Claudia, Postl Matthias, Hunyadi-Gulyas Eva, Darula Zsuzsanna, Domenig Oliver, Sharma Smriti, Lang Irene M, Kiss Attila, Spittler Andreas, Hoetzenecker Konrad, Reindl-Schwaighofer Roman, Krenn Katharina, Ullrich Roman, Wieser Matthias, Grillari-Voglauer Regina, Tretter Verena
Clinical Division of General Anaesthesia and Intensive Care Medicine, Department of Anesthesia, Genera Intensive Care and Pain Therapy, Medical University Vienna, 1090 Vienna, Austria.
Evercyte GmbH, 1110 Vienna, Austria.
Int J Mol Sci. 2025 Jan 15;26(2):683. doi: 10.3390/ijms26020683.
Drug development for human disease relies on preclinical model systems such as human cell cultures and animal experiments before therapeutic treatments can ultimately be tested on humans in clinical studies. We here describe the generation of a novel human cell line (HLMVEC/SVTERT289) that we generated by transfection of microvascular endothelial cells from healthy donor lung tissue with the catalytic domain of telomerase and the SV40 large T/small t-antigen. These cells exhibited satisfactory growth characteristics and largely maintained their native characteristics, including morphology, cell surface marker expression, angiogenic potential and the protein composition of secreted extracellular vesicles. In order to test their suitability as a disease model, we simulated mechanical stress induced by cyclic stretch as encountered in ventilator-induced lung injury using the FlexCell system and compared their performance to primary lung endothelial cells. In this setting, HLMVEC/SVTERT289 cells exhibited significantly higher neprilysin activity on the cell surface and extracellular vesicles secreted from the cell line exhibited higher Tissue Factor and ACE2 expression but lower ACE expression and ACE activity than vesicles released from the primary cells. This study provides an unprecedented and detailed characterization of the HLMVEC/SVTERT289 cell line, which should help to appraise its suitability in different molecular studies.
针对人类疾病的药物研发依赖于临床前模型系统,如人类细胞培养和动物实验,之后才能最终在临床研究中对人类进行治疗测试。我们在此描述一种新型人类细胞系(HLMVEC/SVTERT289)的生成,该细胞系是通过将端粒酶催化结构域以及SV40大T/小t抗原转染至来自健康供体肺组织的微血管内皮细胞而产生的。这些细胞表现出令人满意的生长特性,并在很大程度上保持了其天然特性,包括形态、细胞表面标志物表达、血管生成潜力以及分泌的细胞外囊泡的蛋白质组成。为了测试它们作为疾病模型的适用性,我们使用FlexCell系统模拟了呼吸机诱导的肺损伤中遇到的循环拉伸所诱导的机械应力,并将它们的表现与原代肺内皮细胞进行了比较。在这种情况下,HLMVEC/SVTERT289细胞在细胞表面表现出显著更高的中性肽链内切酶活性,并且该细胞系分泌的细胞外囊泡表现出更高的组织因子和ACE2表达,但与原代细胞释放的囊泡相比,ACE表达和ACE活性更低。这项研究提供了对HLMVEC/SVTERT289细胞系前所未有的详细表征,这应该有助于评估其在不同分子研究中的适用性。